Investor Centre

Resonance Health is a MedTech company listed on the Australian Securities Exchange (ASX:RHT). Resonance Health specialises in the development and commercialisation of non-invasive medical imaging analysis and clinical trial services. We provide innovative industry leading quantitative calculations and evaluations essential in the management of particular diseases, especially in relation to iron overload and hepatic steatosis.

FerriScan® is a non-invasive MRI based solution for quantifying liver iron concentration across the full spectrum seen clinically and is an invaluable tool in the diagnosis and management of patients with all iron overload related conditions.

Cardiac T2* assesses the iron loading in the myocardium. Cardiac T2* may be used on its own or as part of a dual analysis package along with FerriScan® to provide more comprehensive information regarding iron storage in different organs and proper clinical management of risks and treatment plan.

HepaFatScan® gained FDA clearance in December 2013 for the evaluation of fatty liver. FerriScan® and HepaFat-Scan® are analysed in Resonance Health’s image analysis laboratory (Core Lab), which provides quality certified central image analysis services to the clinical community and to clinical trials. Accurate imaging end points are increasingly used in clinical trials, providing quantitative and direct evidence for regulatory submissions.

Since then, Resonance Health has broadened its portfolio with both Core Lab and AI powered products for optimal screening, diagnosis, and management of patients in a variety of clinical settings.

Notice of members’ rights under the Corporation Act 2001 (Cth) in connection with receiving documents 

Resonance Health Ltd ACN 006 762 492 (Resonance or the Company) gives notice according to section 110K of the Corporations Act 2001 (Cth) (Corporations Act), of the rights of members (Shareholders) to: 

• Elect to receive or not receive specific documents; and 
• Make requests to be sent specific documents in physical or electronic form. 

Documents 

Resonance is obliged to send to Shareholders, and Shareholders are entitled to receive: 

• Documents that relate to a meeting of Shareholders, such as a notice of meeting or proxy or voting forms; 
• The Annual Report of Resonance (comprising the financial report, directors’ report and auditor’s report for the relevant financial year); and 
• A notice of members’ rights under section 110K of the Corporations Act (such as this notice) unless the statement is readily available on a website, and any other documents prescribed by relevant regulations (collectively, the Documents). 

Your right to make an election 

Pursuant to the Corporations Act, each Shareholder is entitled to: 

• Elect to be sent Documents in either physical or electronic form; and/or 
• Elect not to be sent the Annual Report of Resonance (and any other documents prescribed by the relevant regulations), by notifying Resonance of their election. 

A Shareholder may make an election in relation to all Documents or a specified class or classes of Documents and is entitled to request that Resonance sends a particular Document to the Shareholder in physical form or in electronic form. 

Notifying Resonance of your election or request 

You can make your election and/or request and notify Resonance by contacting Resonance’s Share Registry directly at admin@advancedshare.com.au. 

Resonance encourages all Shareholders to receive communications electronically. This will allow Shareholders to ensure they stay informed and help our commitment to reducing the negative impact on the environment by minimising paper usage.